BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance

BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.06), $0.11 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $109.33 million versus the consensus estimate of $98.3 million.
Guidance:
Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)—

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• TD Cowen Resumes Keyera Corp. (KEY:CN) (KEYUF) at Buy